As of November 14, 2026, Xilio Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 8, 2026 to June 12, 2026 (Form 8-K, June 12, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Xilio Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-12
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-16
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-01-08
Xilio Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-08 to 2026-06-12. Every row below is cited to the filing it comes from, and this page adds each new change as Xilio Therapeutics, Inc. files it.
Layoffs on record: about 15 jobs, latest 2024-03-28 (layoff filings and notices).
Also on the record for Xilio Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by Coastlands Capital LP | 9.99% of the class | 5%+ stakes | Source |
| November 12, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 7.06% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by StemPoint Capital LP | 9.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by ORBIMED ADVISORS LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by BCLS II Equity Opportunities, LP | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BCLS II Equity Opportunities, LP | 8.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by StemPoint Capital LP | 8.4% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 6.7% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by GILEAD SCIENCES, INC. | 19.9% of the class | 5%+ stakes | Source |
| December 11, 2025 | Stake report, Schedule 13G, by Coastlands Capital LP | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Xilio Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Xilio Therapeutics, Inc. and the records around it.
Xilio Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies: C4 Therapeutics, Inc. (Oct 2025)
- StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026)
- GILEAD SCIENCES, INC. also filed stake reports on 5 other companies: Aspen Neuroscience, Inc. (Nov 2026), Arcus Biosciences, Inc. (Aug 2026), ASSEMBLY BIOSCIENCES, INC. (May 2026)
Watch Xilio Therapeutics, Inc.
Get an email when Xilio Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Xilio Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Xilio Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Xilio Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-12 | Reported | not named in the filing | 8-K, 2026-06-12 | ||
| 2026-04-16 | Reported | not named in the filing | 8-K, 2026-04-16 | ||
| 2026-01-08 | Reported | not named in the filing | 8-K, 2026-01-08 |
New leaders reset buying decisions — get the Full Report on Xilio Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Xilio Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Xilio Therapeutics, Inc.Every change, in the filing's words
Reported
The Board accepted such resignation and immediately re-appointed him as a Class III director.
- In order to achieve a more equal balance of director membership among the three classes of the board of directors (the "Board") of Xilio Therapeutics, Inc. (the "Company") in accordance with the Company's Restated Certificate of Incorporation, as amended, following his re-election as a Class II director at the Company's 2026 annual meeting of stockholders on June 10, 2026 (the "2026 Annual Meeting"), Daniel Curran, M.D., tendered his resignation from his position as a Class II director to the Board, contingent upon his re-appointment as a Class III director.
- Following the rebalancing, the Board consists of three directors in each of Classes I, II and III.
- There were no changes to any of Dr. Curran's compensation arrangements with the Company and there is no compensation due to Dr. Curran as a result of his resignation from the Board and his appointment to the Board as a Class III Director.
- Additionally, at the 2026 Annual Meeting, the Company's stockholders approved the amendment and restatement of the Xilio Therapeutics, Inc. 2021 Stock Incentive Plan (the "Amended and Restated 2021 Plan"), which had previously been adopted by the Board subject to stockholder approval.
Reported
Dr. Blanchard succeeds Christina Rossi, who notified the Company of her decision to resign from the Board and all committees thereof on April 15, 2026, effective as of such date.
- On April 15, 2026, the Board of Directors (the "Board") of Xilio Therapeutics, Inc. (the "Company"), on the recommendation of the Nominating and Corporate Governance committee of the Board, elected Cheryl R. Blanchard, Ph.D., as a Class III director of the Company, with a term expiring at the Company's 2027 annual meeting of stockholders, to serve until her successor has duly been elected and qualified or until her earlier resignation, death or removal.
- In connection with her election to the Board, Dr. Blanchard was appointed as chair of the Compensation Committee of the Board and as a member of the Audit Committee of the Board.
- Specifically, Dr. Blanchard will receive an annual cash fee of $40,000 for service as a Board member and an additional annual cash fee of $12,000 for service as chair of the Compensation Committee of the Board and $7,500 for service as a member of the Audit Committee.
- Each such stock option will have an exercise price equal to the closing price of the Company's common stock as reported on Nasdaq on the date of grant and will expire ten years after the grant date.
- Ms. Rossi's resignation did not result from any disagreement with the Company or its management.
Reported
On January 8, 2026, the Company announced the appointment of Sara M. Bonstein as chair of the Board.
- Ms. Bonstein succeeds Paul Clancy, who notified the Company of his decision to retire from the Board on January 6, 2026, effective as of such date.
- Mr. Clancy's retirement did not result from any disagreement with the Company or its management.
Tools for this story
Each opens in a new tab, filled in for Xilio Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
